Piracetam as an adjuvant to language therapy for aphasia: A randomized double-blind placebo-controlled pilot study

Archives of Physical Medicine and Rehabilitation

Volumn 78, Issue 3, 1997, Pages 245-250

  Huber, Walter ^a   Willmes, Klaus ^a   Poeck, Klaus ^a   Van Vleymen, Betty ^b   Deberdt, Walter ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Preclinical CNS Research   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PIRACETAM;

ADULT; AGED; APHASIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; READING; SCORING SYSTEM; SPEECH THERAPY; TREATMENT OUTCOME;

EID: 0030935590     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9993(97)90028-9     Document Type: Article

References (52)

1. Wade D, Langton Hewer R, David R, Enderby P. Aphasia after stroke: natural history and associated deficits. J Neurol Neurosurg Psychiatry 1986;49:11-6.
2. Bachman DL, Albert ML. The pharmacotherapy of aphasia: historical perspective and directions for future research. Aphasiology 1990;4:407-13.
3. Small SL. Pharmacotherapy of aphasia: a critical review. Stroke 1994;25:1282-9.
4. Walker-Batson D, Unwin H, Curtis S, Allen IE, Wood M, Smith P, et al. Use of amphetamine in the treatment of aphasia. Neurol Neurosci 1992;4:47-50.
5. Hacki T, Kenklies M, Hofmann R, Hafenkamp G. Pharmakotherapie von Stimm-und Artikulationsstörungen bei Aphasie. Folia Phoniatr 1990;42:283-8.
6. Wertz RT. Efficacy of various methods. In: Paradis M, editor. Foundations of aphasia rehabilitation. Oxford: Pergamon Press, 1993: 61-75.
7. Poeck K, Huber W, Willmes K. Outcome of intensive language treatment in aphasia. J Speech Hear Res 1989;54:471-9.
8. Springer L, Willmes K. Efficacy of language systematic learning-approaches to treatment. In: Paradis M, editor. Foundations of aphasia rehabilitation. Oxford: Pergamon Press, 1993:77-97.
9. Basso A. Prognostic factors in aphasia. Aphasiology 1992;6:337-48.
10. Methé S, Huber W, Paradis M. Inventory and classification of rehabilitation methods. In: Paradis M, editor. Foundations of aphasia rehabilitation. Oxford: Pergamon Press, 1993:3-30.
11. Basso A, Capitani E, Vignolo LA. Influence of rehabilitation on language skills in aphasic patients. A controlled study. Arch Neurol 1979;36:190-6.
12. Wertz RT, Weiss DG, Aten JL, Brookshire RH, Garcia-Buñuel L, Holland AL, et al. Comparison of clinic, home and deferred language treatment for aphasia. A Veterans Administration Cooperative Study. Arch Neurol 1986;43:653-8.
13. Robey RR. The efficacy of treatment for aphasic persons: a meta-analysis. Brain Lang 1994;47:582-608.
14. Lincoln NB, McGuirk E, Mulley GP, Lendrem W, Mitchell JRA. Effectiveness of speech therapy for aphasic stroke patients. Lancet 1984;1:1197-200.
15. Hartman J, Landau WM. Comparison of formal language therapy with supportive counseling for aphasia due to acute vascular accident. Arch Neurol 1987;44:646-9.
16. Meikle M, Wechsler E, Tupper A-M, Beenson M, Butler J, Mulhall D, et al. Comparative trial of volunteer and professional treatments of dysphasia after stroke. BMJ 1979;2:87-9.
17. David R, Enderby P, Bainton D. Treatment of acquired aphasia: speech therapists and volunteers compared. J Neurol Neurosurg Psychiatry 1982;45:957-61.
18. Shewan CM, Kertesz A. Effects of speech and language treatment on recovery from aphasia. Brain Lang 1984;23:272-99.
19. Wertz RT, Collins MJ, Weiss D, Kurtzke JF, Friden T, Brookshire RH, et al. Veterans Administration cooperative study on aphasia: a comparison of individual and group treatment. J Speech Hear Res 1981;24:580-94.
20. Giurgea C. Piracetam: nootropic pharmacology of neurointegrative activity. In: Current developments in psychopharmacology. Spectrum Publications 1976;3:222-73.
21. Cohen S, Müller W. Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. Pharmacology 1993; 47:217-22.
22. Müller W, Hartmann H, Koch S, Scheuer K, Stoll S. Neurotransmission in aging-therapeutic aspects. In: Racagni G, Brunello N, Langer SZ, editors. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. Int Acad Biomed Drug Res, Basel: Karger 1994;7:166-73.
23. Gobert JG. Genèse d'un médicament: le piracetam. Métabolisation et recherche biochimique. J Pharm Belg 1972;27:281-304.
24. Müller WE. Age-related quantitative and qualitative receptor changes and pharmacological reactivity. In: Racagni G, Mendlewicz J, editors. Treatment of age-related cognitive dysfunction: pharmacological and clinical evaluation. Int Acad Biomed Drug Res, Basel: Karger, 1992;2:35-40.
25. Giurgea C, Mouravieff-Lesuisse F, Leemans R. Corrélations électro-pharmacologiques au cours de l'anoxie oxyprive chez le lapin en respiration libre ou artificielle. Rev Neurol (Paris) 1970;122/6:484-6.
26. Giurgea C, Mouravieff-Lesuisse F. Central hypoxia models and correlations with aging brain. Neuropsychopharmacology 1978;2: 1623-31.
27. Henry RL, Nalbandian RM, Dzandu JK. Effect of membrane-bound protein phosphorylation of intact normal and diabetic human erythrocytes: enhanced membrane deformability [abstract]. Diabetes 1981;30 Suppl:83a.
28. Fleischman JA. Piracetam's effect on sickle and diabetic erythrocytes as demonstrated in enucleated human eye trabecular meshwork filterability studies: clinical implications. In: Proceedings of the 10th International Symposium on Nootropic Agents: 1982 Oct 13; Paris. Brussels: UCB, 1982:61-7.
29. Bick RL, Farced J, Skondia Y. Piracetam: a new platelet suppressing drug [abstract]. Thromb Haemost 1981;46:67.
30. Moriau M, Crasborn L, Lavenne-Pardonge E, von Frenckell R, Col-Debeys C. Platelet anti-aggregant and rheological properties of piracetam. Arzneimittelforschung 1993;43(1)/2:110-8.
31. Moriau M, Lavenne-Pardonge E, Crasborn L, von Frenckell R, Col-Debeys C. Treatment of the Raynaud's phenomenon with piracetam. Arzneimittelforschung 1993;43(1):526-35.
32. Grotemeyer KH, Hofferberth G, Hirschberg M. Normalisierung hyperreaktiver Thrombozyten bei Patienten mit Tia's unter Piracetam? Nervenarzt 1986;57(3):180-3.
33. Reuse-Blom S, Polderman J. Influence of piracetam upon the pial microcirculation. In: Loose DE, Loose DA, editors. Sechstes Internatzionales Angiologisches und Angiographisches Seminar: 1979 Mar 15-17; Baden-Baden, Germany. Gefäss-Patient-Therapie. Baden-Baden, Germany: Witzstrock, 1980:62-4.
34. 15-oxygen [abstract]. In: Bes A, editor. Senile Dementias. Proceedings of an international symposium organized by SIR International: 1986 Oct 27-29; Paris. Paris: Libbey Eurotext, 1986.
35. Herrschaft H. Die Wirksamkeit von Piracetam bei der akuten zerebralen Ischämie des Menschen. Med Klin 1988;83:667-77.
36. Platt D, Horn J, Summa J-D, Schmitt-Ruth R, Reinlein B, Kauntz J, et al. Zur Wirksamkeit von piracetam bei geriatrischen Patienten mit akuter zerebraler Ischämie. Eine klinisch kontrollierte Doppelblindstudie. Med Welt 1992;43:181-90.
37. Enderby P, Broeckx J, Hospers W, Schildermans F, Deberdt W. Effects of piracetam on recovery and rehabilitation after stroke. Clin Neuropharmacol 1994;17:320-31.
38. Poeck K, Huber W, Willmes K. Piracetam as add-on treatment to intensive speech therapy for aphasia [abstract]. In: Proceedings of the Second International Conference on Stroke: 1993 May 12-15; Geneva. Geneva: World Health Federation, 1993.
39. Huber W, Poeck K, Willmes K. Der Aachener Aphasie Test. Göttingen, Germany: Hogrefe, 1983.
40. Huber W, Poeck K, Willmes K. The Aachen Aphasia Test. In: Rose FC, editor. Advances in neurology: progress in aphasiology. New York: Raven Press, 1984:291-303.
41. Huber W. Therapy of aphasia: comparison of various approaches. In: von Steinbüchel N, von Cramon DY, Pöppel E, editors. Neuropsychological rehabilitation. Berlin: Springer, 1992:242-56.
42. Huber W, Springer L, Willmes K. Approaches to aphasia therapy in Aachen. In: Holland AL, Forbes MM, editors. Aphasia treatment-world perspectives. San Diego: Singular Publishing Group, 1993: 55-86.
43. De Renzi D, Vignolo L. The token test: a sensitive test to detect receptive disturbances in aphasias. Brain 1962;85:665-78.
44. Willmes K, Poeck K, Weniger D, Huber W. Facet theory applied to the construction and validation of the Aachen Aphasia Test. Brain Lang 1983;18:259-76.
45. Willmes K. An approach to analyzing a single subject's scores obtained in a standardized test with application to the Aachen Aphasia Test (AAT). J Clin Exp Neuropsych 1985;7:331-52.
46. Gibbons JD, Chakraborti S. Nonparametric statistical inference. 3rd ed. New York: Marcel Dekker, 1992.
47. Huber HP. Psychometrische Einzelfalldiagnostik. Weinheim, Germany: Beltz, 1973.
48. Heiss W-D, Kessler J, Karbe H, Fink GR, Pawlik G. Cerebral glucose metabolism as a predictor of recovery from aphasia in ischemic stroke. Arch Neurol 1993;50:958-64.
49. Heiss W-D, Ilsen HW, Wagner R, Pawlik G, Wienhard K. Remote functional depression of glucose metabolism in stroke and its alteration by activating drugs. In: Heiss W-D, Phelps ME, editors. Positron emission tomography of the brain. Berlin: Springer-Verlag, 1983:162-8.
50. Giurgea C, Moyersoons F. The pharmacology of callosal transmission: a general survey. In: Russell I, Van Hof M, Berlucchi G, editors. Structure and function of cerebral commissures. London: Macmillan, 1979:283-98.
51. Dimond S. Drugs to improve learning in man: implications and neuropsychological analysis. In: Knight R, Bakker O, editors. The neuropsychology of learning disorders. London: University Park Press, 1979:367-79.
52. Weiller C, Isensee Ch, Rijntjes M, Huber W, Müller S, Bier D, et al. Recovery from Wernicke's aphasia: a positron emmission tomographic study. Ann Neurol 1995;37:723-32.